Abdominal obesity and the level of markers of lower respiratory tract damage in patients with chronic bronchitis

Kashtanova E.V.; Polonskaya Ya.V.; Scherbakova L.V.; Logvinenko I.I.; Kurtukov E.F.; Denisova D.V.; Ragino Yu.I.

doi:https://doi.org/10.17116/profmed20212405135

Kashtanova E.V.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences

Polonskaya Ya.V.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences

Scherbakova L.V.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences

Logvinenko I.I.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences

Kurtukov E.F.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences

Denisova D.V.

Research Institute of Therapy and Preventive Medicine — branch of Federal Research Center Institute of Cytology and Genetics

Ragino Yu.I.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences

Abdominal obesity and the level of markers of lower respiratory tract damage in patients with chronic bronchitis

Authors:

Kashtanova E.V., Polonskaya Ya.V., Scherbakova L.V., Logvinenko I.I., Kurtukov E.F., Denisova D.V., Ragino Yu.I.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2021;24(5): 35‑40

DOI: 10.17116/profmed20212405135

Read: 2098 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kashtanova EV, Polonskaya YaV, Scherbakova LV, Logvinenko II, Kurtukov EF, Denisova DV, Ragino YuI. Abdominal obesity and the level of markers of lower respiratory tract damage in patients with chronic bronchitis. Russian Journal of Preventive Medicine. 2021;24(5):35‑40. (In Russ.)
https://doi.org/10.17116/profmed20212405135

Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)

Использование инфографики авторами научных работ

Close metadata

Abstract:

Chronic bronchitis is a very acute problem not only in Russia, but also around the world. Recently, the literature describes the clinical and functional features of the combined course of chronic bronchitis and abdominal obesity, which is a predictor of an unfavorable prognosis of this pathology.

OBJECTIVE

To study the association of abdominal obesity with markers of lower respiratory tract damage such as surfactant proteins A and D, α1-antitrypsin, Clara cell protein, pulmonary and activation- regulated chemokine in patients with chronic bronchitis.

MATERIAL AND METHODS

The study included 64 patients who underwent a screening examination at the NIITPM branch of the ICiG SB RAS. The patients were interviewed for the detection of respiratory diseases, spirometry, and anthropometry. All patients were divided into two groups: 1—37 patients with chronic bronchitis (CKD) in combination with abdominal obesity, 2—27 patients with chronic bronchitis without abdominal obesity. Serum levels of serum surfactant protein A, serum surfactant protein D, α1-antitrypsin, Clara cell protein (CC16), and pulmonary and activation- regulated chemokine (PARC) were determined by enzyme immunoassay.

RESULTS

The level of serum surfactant protein D is significantly lower in the group of patients with CKD in combination with abdominal obesity. The content of PARC was 43% higher in the group of patients with abdominal obesity. In women, the level of PARC was increased by 1.42 times, and in men by 1.35 times. There were no statistically significant differences between the groups for serum surfactant protein A, α1-antitrypsin, and CC16. When conducting the correlation analysis revealed a connection between the level of lung CC chemokine regulated activation with BMI (r=0.499; p<0.01) and waist circumference (r=0.493; p<0.01).

CONCLUSION

In patients with chronic bronchitis, the presence of abdominal obesity is associated with a significant change in the levels of markers of lower respiratory tract damage, such as pulmonary and activation- regulated chemokine and surfactant protein D.

Keywords:

chronic bronchitis

abdominal obesity

surfactant A

surfactant D

α1-antitrypsin

Clara cell protein (CC16)

pulmonary and activation- regulated chemokine (PARC)

Authors:

Kashtanova E.V.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences

Polonskaya Ya.V.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences

Scherbakova L.V.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences

Logvinenko I.I.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences

Kurtukov E.F.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences

Denisova D.V.

Research Institute of Therapy and Preventive Medicine — branch of Federal Research Center Institute of Cytology and Genetics

Ragino Yu.I.

Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences

Received:

30.11.2020

Accepted:

20.02.2021

Close metadata

References:

Obshchaya zabolevaemost’ vsego naseleniya Rossii v 2017 godu. Statisticheskie materialy. Chast’ 2. M.: MZ RF; 2018. Accessed March 27, 2021. (In Russ.). https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2017-god
Zammit C, Liddicoat H, Moonsie I, Makker H. Obesity and respiratory diseases. International Journal of General Medicine. 2010;3(4):335-343. https://doi.org/10.2147/IJGM.S11926
Boikov VA, Kobyakova OS, Deev IA, Kulikov ES, Starovoitova EA. The state of external respiratory function in obese patients. Bûlletenʹ sibirskoj mediciny. 2013;12(1):86-92. (In Russ.).
Foumani AA, Neyaragh MM, Ranjbar ZA, Leyli EK, Ildari S, Jafari A.Waist Circumference and Spirometric Measurements in Chronic Obstructive Pulmonary Disease. Osong Public Health Res Perspect. 2019;10(4):240-245. https://doi.org/10.24171/j.phrp.2019.10.4.07
Behrens G, Matthews CE, Moore SC, Hollenbeck AR, Leitzmann MF Body size and physical activity in relation to incidence of chronic obstructive pulmonary disease. CMAJ. 2014;186(12):E457-469. https://doi.org/10.1503/cmaj.140025
Akpinar EE, Akpinar S, Ertek S, Sayin E, Gulhan M. Systemic inflammation and metabolic syndrome in stable COPD patients. Tuberkulozve Toraks. 2012;60:230-237. https://doi.org/10.5578/tt.4018
Vujic T, Nagorni O, Maric G, Popovic L, Jankovic J. Metabolic syndrome in patients with chronic obstructive pulmonary disease: frequency and relationship with systemic inflammation. Hippokratia. 2016;20(2):110-114.
Kokosov AN. Chronic non-obstructive bronchitis. Klinicheskaya medicina. 1999;1:11-16. (In Russ.).
Sin DD, Miller BE, Duvoix A, Man SF, Zhang X, Silverman EK, Connett JE, Anthonisen NA, Wise RA, Tashkin D, Celli BR, Edwards LD, Locantore N, Macnee W, Tal-Singer R, Lomas DA; ECLIPSE Investigators. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(9):1187-1192. https://doi.org/10.1164/rccm.201008-1220OC
Pinto-Plata V, Casanova C, Müllerova H, de Torres JP, Corado H, Varo N, Cordoba E, Zeineldine S, Paz H, Baz R, Divo M, Cortopassi F, Celli BR. Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. Respir Res. 2012;13(1):71. https://doi.org/10.1186/1465-9921-13-71
Dilektasli AG, Demirdogen Cetinoglu E, Uzaslan E, Budak F, Coskun F, Ursavas A, Ercan I, Ege E. Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization. Int J Chron Obstruct Pulmon Dis. 2017;12:199-208. https://doi.org/10.2147/COPD.S118424
Kishore U, Greenhough TJ, Waters P, Shrive AK, Ghai R, Kamran MF, Bernal AL, Reid KB, Madan T, Chakraborty T. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol. 2006;43(9):1293-1315. https://doi.org/10.1016/j.molimm.2005.08.004
Orgeig S, Hiemstra PS, Veldhuizen EJ, Casals C, Clark HW, Haczku A, Knudsen L, Possmayer F. Recent advances in alveolar biology: evolution and function of alveolar proteins. Respir Physiol Neurobiol. 2010;173:43-54. https://doi.org/10.1016/j.resp.2010.04.023
Lyamina SV, Vedenikin TYu, Malyshev IYu. A modern approach to the analysis of the immune response in lung diseases: surfactant protein D and its role. Sovremennyye problemy nauki i obrazovaniya. 2011;4:1-4. (In Russ.).
Hartl D, Griese M. Surfactant protein D in human lung diseases. Eur J Clin Invest. 2006;36(6):423-435. https://doi.org/10.1111/j.1365-2362.2006.01648.x
Ju CR, Liu W, Chen RC. Serum surfactant protein D: biomarker of chronic obstructive pulmonary disease. Dis Markers. 2012;32(5):281-287. https://doi.org/10.3233/DMA-2011-0887
Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigators. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J. 2009;34(1):95-102. https://doi.org/10.1183/09031936.00156508
Shiels MS, Chaturvedi AK, Katki HA, Gochuico BR, Caporaso NE, Engels EA. Circulating markers of interstitial lung disease and subsequent risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2262-2272. https://doi.org/10.1158/1055-9965.EPI-11-0326
Sin DD, Leung R, Gan WQ, Man SP. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med. 2007;7:13. https://doi.org/10.1186/1471-2466-7-13
Winkler C, Atochina-Vasserman EN, Holz O, Beers MF, Erpenbeck VJ, Krug N, Roepcke S, Lauer G, Elmlinger M, Hohlfeld JM. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res. 2011;12:29. https://doi.org/10.1186/1465-9921-12-29
Shakoori TA, Sin DD, Ghafoor F, Bashir S, Bokhari SN. Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease. Dis Markers. 2009;27(6):287-294. https://doi.org/10.3233/DMA-2009-0674
Eisner MD, Parsons P, Matthay MA, Ware L, Greene K; Acute Respiratory Distress Syndrome Network. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax. 2003;58(11):983-988. https://doi.org/10.1136/thorax.58.11.983
Jawed S, Mannan N, Qureshi MA. Association of Surfactant Protein-D with Obesity. J Ayub Med Coll Abbottabad. 2016;28(3):489-492.
Broeckaert F, Clippe A, Knoops B, Hermans C, Bernard A. Clara cell secretory protein (CC16): features as a peripheral lung biomarker. Ann NY Acad Sci. 2000;923:68-77. https://doi.org/10.1111/j.1749-6632.2000.tb05520.x
Guerra S, Vasquez MM, Spangenberg A, Halonen M, Martin RJ. Club cell secretory protein in serum and bronchoalveolar lavage of patients with asthma. J Allergy Clin Immunol. 2016;138:932-934. https://doi.org/10.1016/j.jaci.2016.03.047
Laucho-Contreras ME, Polverino F, Tesfaigzi Y, Pilon A, Cell BR, Owen CA. Club cell protein 16 (CC16) augmentation: a potential disease-modifying approach for chronic obstructive pulmonary disease (COPD). Expert Opin Ther Targets. 2016;20:8690-8883. https://doi.org/10.1517/14728222.2016.1139084
Petersen H, Leng S, Belinsky SA, Miller BE, Tal-Singer R, et al. Low plasma CC16 levels in smokers are associated with higher risk for chronic bronchitis. Eur Respir J. 2015;46:1501-1503. https://doi.org/10.1183/13993003.00682-2015
Guerra S, Vasquez MM, Spangenberg A, Halonen M, Martin RJ. Club cell secretory protein in serum and bronchoalveolar lavage of patients with asthma. J Allergy Clin Immunol. 2016;138(3):932-934. https://doi.org/10.1016/j.jaci.2016.03.047
Chuchalin AG, Tseymakh IYa, Momot AP, Mamaev AN, Karbyshev IA, Kostyuchenko GI. Changes in systemic inflammatory and hemostatic response in patients with co-morbidity of exacerbation of chronic obstructive pulmonary disease, chronic heart failure and obesity. Russian Pulmonology. 2014;6:25-32. (In Russ.). https://doi.org/10.18093/0869-0189-2014-0-6-25-32
Shijubo N, Itoh Y, Yamaguchi T, et al. Serum and BAL Clara cell 10 kDa protein (CC10) levels and CC10-positive bronchiolar cells are decreased in smokers. Eur Respir J. 1997;10(5):1108-1114. https://doi.org/10.1183/09031936.97.10051108
Rava M, Tares L, Lavi I, et al. Serum levels of Clara cell secretory protein, asthma, and lung function in the adult general population. J Allergy Clin Immunol. 2013;132(1):230-232. https://doi.org/10.1016/j.jaci.2013.01.023